Finally, the functional implications of these findings, including the molecular mechanisms underlying disease in DM patients with anti-TIF1γ autoantibodies and the relationship between autoantibody binding sites and clinical manifestations, require further investigation. This evidence concerns the gene TRIM33 and dermatomyositis.